Navigation Links
Biomarkers May Predict Alzheimer's
Date:7/21/2009

Proteins in spinal fluid may help diagnose disease early, study shows,,

TUESDAY, July 21 (HealthDay News) -- Certain proteins found in cerebrospinal fluid may accurately identify the people with mild cognitive impairment who are most likely to develop Alzheimer's disease, a new study finds.

Changes in the chemistry of cerebrospinal fluid have been identified as early signs of Alzheimer's disease. If and when treatments are available for Alzheimer's, diagnosing the disease early may help prevent it from developing, experts say.

"We confirmed, in a large multi-center study, that proteins in cerebrospinal fluid identify early-stage Alzheimer's disease, as suggested by previous smaller studies," said lead researcher Dr. Niklas Mattsson, from the Institute of Neuroscience and Physiology, Clinical Neurochemistry Laboratory at Sahlgrenska University Hospital in Molndal, Sweden.

"These proteins may be used in research, in particular in drug trials, and also as a complement to clinical diagnostics, in particular when disease-modifying drugs become available," he said.

The report is published in the July 22/29 issue of the Journal of the American Medical Association.

For the study, Mattsson's team studied the accuracy of using three biomarkers found in spinal fluid in predicting Alzheimer's diseases. The biomarkers are beta-amyloid1-42 (Aβ42), total tau protein (T-tau), and tau phosphorylated at position threonine 181 (P-tau).

The researchers tested for these biomarkers in 750 people with mild cognitive impairment, 529 people with Alzheimer's disease and 304 healthy people. After two years, 271 of those with mild cognitive impairment progressed to Alzheimer's disease and 59 developed other dementias.

The researchers found that people who developed Alzheimer's had lower levels of Aβ42 and higher levels of P-tau and T-tau compared with patients with mild cognitive impairment who did not develop Alzheimer's.

Mattsson's group found these biomarkers were highly accurate in predicting which patients would develop Alzheimer's disease. "The cerebrospinal fluid proteins Aβ42, T-tau, and P-tau are useful in diagnosis of early-stage Alzheimer's disease," Mattsson noted.

Dr. Sam Gandy, the Mount Sinai Professor in Alzheimer's Disease Research at Mount Sinai School of Medicine in New York City, said this study really quantifies the accuracy of these tests in predicting Alzheimer's.

"There have been a number of smaller reports that Aβ falls and P-tau rises as the clinical course progresses from aging to mild cognitive impairment to Alzheimer's," Gandy said. "The sensitivities and specificities of these smaller studies have varied widely."

This larger study is definitive in establishing sensitivity and specificity that are somewhat lower than those reported by the smaller studies, Gandy said. "The larger study also points up the importance of harmonizing assays across multiple study sites in order to optimize the sensitivity and specificity."

Maria Carrillo, director of medical and scientific relations at the Alzheimer's Association, hopes that one day Alzheimer's can be screened for as routinely as cholesterol levels are checked today.

"We are very excited that cerebrospinal fluid biomarkers are holding up in terms of their specificity and sensitivity in diagnosing the disease early," Carrillo said. "The next step is to make sure these tests are standardized so that the test will mean the same thing, no matter where it is taken."

If these tests are standardized, it could be a biomarker that identifies the disease, Carrillo said. "If over the next two or three years we also have a therapy, then we need to examine how that therapy works in an incipient form of Alzheimer's, not once those memories have already started fading," she said.

More information

For more information on Alzheimer's disease, visit the Alzheimer's Association.



SOURCES: Niklas Mattsson, M.D., Institute of Neuroscience and Physiology, Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Molndal, Sweden; Maria Carrillo, Ph.D., director, medical and scientific relations, Alzheimer's Association; Samuel Gandy, M.D., Ph.D., Mount Sinai Professor in Alzheimer's Disease Research, Mount Sinai School of Medicine, New York City; July 22/29, 2009, Journal of the American Medical Association


'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. DiaGenic to Provide MCI Biomarkers for Merz Pharmaceuticals
2. Biomarkers predict brain tumors response to therapy
3. Novel biomarkers in heart failure
4. Biomarkers May Help Measure Rate of Decline in Dementia
5. Interleukin Genetics to Chair Expert Panel Discussion on Use of Biomarkers in Drug Development at BIO Convention
6. BioTech Firm Decodes Current Swine Flu BioMarkers
7. Biomarkers May Predict Aggressiveness of Prostate Cancer
8. Vitamin D Linked to HDL Cholesterol - Shaklee Corporation Research Links Vitamin D with Key Biomarkers for Metabolic Syndrome and Heart Disease
9. Potential lung disease biomarkers yield clues to COX-2 inhibitor side effects
10. Cordex Pharma to Collaborate with BG Medicine in a Clinical Study of Heart Failure Biomarkers
11. Biomarkers detected for Chikungunya fever
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Biomarkers May Predict Alzheimer's 
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/26/2016)... ... , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... a whole new perspective by using the title layers in ProSlice Levels to ... ProSlice Levels contains over 30 Different presets to choose from. FCPX users ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 According to ... Type (Standard Pen Needles, Safety Pen Needles), Needle Length ... Growth Hormone), Mode of Purchase (Retail, Non-Retail) - Trends ... report studies the market for the forecast period of ... USD 2.81 Billion by 2021 from USD 1.65 Billion ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
Breaking Medicine Technology: